BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · IEX Real-Time Price · USD
27.74
+0.71 (2.63%)
At close: May 2, 2024, 4:00 PM
28.10
+0.36 (1.30%)
After-hours: May 2, 2024, 5:56 PM EDT
BridgeBio Pharma Employees
BridgeBio Pharma had 550 employees on December 31, 2023. The number of employees increased by 158 or 40.31% compared to the previous year.
Employees
550
Change (1Y)
158
Growth (1Y)
40.31%
Revenue / Employee
$16,915
Profits / Employee
-$1,169,458
Market Cap
5.19B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 550 | 158 | 40.31% |
Dec 31, 2022 | 392 | -186 | -32.18% |
Dec 31, 2021 | 578 | 193 | 50.13% |
Dec 31, 2020 | 385 | 137 | 55.24% |
Dec 31, 2019 | 248 | 96 | 63.16% |
Dec 31, 2017 | 152 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Bausch + Lomb | 13,300 |
Organon & Co. | 10,000 |
Option Care Health | 7,802 |
Haemonetics | 3,034 |
Doximity | 977 |
Glaukos | 907 |
Lantheus Holdings | 834 |
BBIO News
- 11 hours ago - BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 22 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - GlobeNewsWire
- 2 months ago - BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - BridgeBio Pharma Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe - Reuters
- 2 months ago - BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM - GlobeNewsWire
- 2 months ago - BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update - GlobeNewsWire